Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will dis­con­tin­ue the glob­al de­vel­op­ment pro­gram of am­cen­es­trant, the se­lec­tive es­tro­gen re­cep­tor de­grad­er once billed as a top late-stage prospect. Hav­ing al­ready failed a Phase II monother­a­py test ear­li­er this year, a com­bo with the drug al­so missed the bar in a sec­ond tri­al for breast can­cer, trig­ger­ing the de­ci­sion to drop the whole pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER